254
Views
7
CrossRef citations to date
0
Altmetric
Articles

Patients’ self-report anxiety, depression and quality of life and their predictive factors in muscle invasive bladder cancer patients receiving adjuvant chemotherapy

, , & ORCID Icon
Pages 190-200 | Received 18 Nov 2018, Accepted 17 Oct 2019, Published online: 08 Nov 2019
 

ABSTRACT

This study aimed to evaluate anxiety, depression and quality of life (QoL) by patients’ self-report scales and the predictive factors for their aggravation in muscle invasive bladder cancer (MIBC) patients receiving adjuvant chemotherapy. One hundred and ninety-four MIBC patients who received adjuvant chemotherapy and underwent radical cystectomy were consecutively enrolled. HADS was used to evaluate anxiety and depression, and EORTC QLQ-C30 Scale was used to assess QoL. Post adjuvant chemotherapy, HADS-Anxiety score (P = 0.042), anxiety percentage (P = 0.036), HADS-Depression score (P < 0.001), depression percentage (P = 0.002) and the EORTC QLQ-C30 Functional score (P = 0.002) were elevated compared with baseline. Age (P < 0.001), BMI (P = 0.021) and hypertension (P = 0.001) correlated with aggravation of HADS-Anxiety score, while gender (P < 0.001) correlated with aggravation of HADS-Depression score independently during adjuvant chemotherapy. And smoking, alcohol use, hypertension, diabetes, ECOG performance, pT stage as well as pN stage independently predicted the worsening of EORTC QLQ-C30 Scale subscale scores during adjuvant chemotherapy (all P < 0.05). In conclusion, patients’ self-report anxiety and depression were increased while QoL was not deteriorated in MIBC patients during adjuvant chemotherapy, and age, gender, BMI, hypertension, smoking, alcohol use, diabetes, ECOG performance, pT stage as well as pN stage were potential predicting factors for their aggravation.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.